Patients With Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening A Large Cohort Analysis

被引:75
|
作者
Moua, Teng [1 ]
Westerly, Blair D. [1 ]
Dulohery, Megan M. [1 ]
Daniels, Craig E. [1 ]
Ryu, Jay H. [1 ]
Lim, Kaiser G. [1 ]
机构
[1] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA
关键词
acute respiratory decline; fibrotic interstitial lung disease; hospitalization; IDIOPATHIC PULMONARY-FIBROSIS; ACUTE EXACERBATION; CLINICAL-FEATURES; PNEUMONIA;
D O I
10.1016/j.chest.2015.12.026
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Acute respiratory worsening (ARW) requiring hospitalization in patients with fibrotic interstitial lung disease (f-ILD) is common. Little is known about the frequency and implications of ARW in IPF and non-IPF ILD patients hospitalized for acute exacerbation (AE) vs known causes of ARW. METHODS: All consecutive patients with f-ILD hospitalized with ARW at our institution from 2000 to 2014 were reviewed. ARW was defined as any worsening of respiratory symptoms with new or worsened hypoxemia or hypercapnia within 30 days of admission. Suspected AE was defined using modified 2007 American Thoracic Society/European Respiratory Society criteria. Known causes of ARW were reviewed and collated along with in-hospital and all-cause mortality postdischarge. RESULTS: A total of 220 patients (100 with IPF and 120 non-IPF) composed 311 admissions for ARW. Suspected AE (SAE) comprised 52% of ARW admissions, followed by infection (20%), and subacute progression of disease (15%). In-hospital mortality was similar in patients with IPF vs patients without (55 vs 45%, P = .18), but worse in suspected AE admission types (OR, 3.1 [1.9-5.14]). One-year survival after last ARW admission for the whole cohort was 22%, despite only 27% of patients presenting with baseline oxygen requirement at admission and a mean admission Charlson Comorbidity Index score of 5.4 (expected 1-year survival, 89%). Survival after discharge was similar between SAE and secondary ARW admission types in both IPF and non-IPF patients. CONCLUSIONS: Among patients with f-ILD, hospitalization for ARW appears associated with significant in-hospital and postdischarge mortality regardless of underlying fibrotic lung disease or non-AE cause of acute respiratory decline.
引用
收藏
页码:1205 / 1214
页数:10
相关论文
共 50 条
  • [41] Characteristics of Arterial Blood Gas in Patients With Fibrotic Interstitial Lung Disease
    Donaldson, M.
    Donohoe, K.
    Min, B.
    Durand, C.
    Johannson, K. A.
    Lok, S. D.
    Manganas, H.
    Marcoux, V.
    Morisset, J.
    Ryerson, C. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [42] Frailty Is an Independent Predictor of Mortality in Patients with Fibrotic Interstitial Lung Disease
    Guler, S. A.
    Kwan, J. M.
    Wilcox, P. G.
    Ryerson, C. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [43] Evaluating the Frequency and Impact of Hospitalization in Patients with Fibrotic Interstitial Lung Disease
    Mazzetti, T.
    Farooqi, M.
    Dvorkin-Gheva, A.
    Wongkarnjana, A.
    Chong, S.
    Alobaid, F.
    Sakkat, A.
    Almusally, R.
    Vermunt, D.
    Scallan, C. J.
    Kolb, M. R.
    Cox, G. P.
    Hambly, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [44] Nocturnal hypoxaemia is associated with mortality in patients with fibrotic interstitial lung disease
    Myall, K.
    Martinovic, J.
    Wu, Z.
    Lam, J.
    Roque, D.
    Jardim, V
    Jackson, D. J.
    Suh, E.
    Maher, T.
    Molyneaux, P.
    Kent, B.
    West, A.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [45] OBSTRUCTIVE SLEEP APNEA IN PATIENTS WITH COPD AND FIBROTIC INTERSTITIAL LUNG DISEASE
    Zhang Xiaolei
    Zhang Hui
    Gao Bo
    Han Teng
    Zhang Li
    Dai Huaping
    SLEEP, 2019, 42
  • [46] Fibrotic or nonfibrotic interstitial lung disease in patients with primary Sjogren syndrome
    Luppi, Fabrizio
    Ferrara, Giovanni
    Faverio, Paola
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2023, 133 (02):
  • [47] Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease
    Algamdi, Mohmmed
    Sadatsafavi, Mohsen
    Fisher, Jolene
    Morisset, Julie
    Johannson, Kerri
    Fell, Charlene
    Kolb, Martin
    Manganas, Helene
    Cox, Gerard
    Gershon, Andrea
    Halayko, Andrew
    Hambly, Nathan
    Khalil, Nasreen
    Shapera, Shane
    To, Teresa
    Wilcox, Pearce
    Guler, Sabina
    Ryerson, Christopher
    CHEST, 2019, 156 (05) : 887 - 895
  • [48] Immune mechanisms in fibrotic interstitial lung disease
    Kamiya, Mari
    Carter, Hannah
    Espindola, Milena S.
    Doyle, Tracy J.
    Lee, Joyce S.
    Merriam, Louis T.
    Zhang, Fan
    Kawano-Dourado, Leticia
    Sparks, Jeffrey A.
    Hogaboam, Cory M.
    Moore, Bethany B.
    Oldham, William M.
    Kim, Edy Y.
    CELL, 2024, 187 (14) : 3506 - 3530
  • [49] Quantitative CT of fibrotic interstitial lung disease
    Lynch, David A.
    CHEST, 2007, 131 (03) : 643 - 644
  • [50] Clinical implications of frailty assessed in hospitalized patients with acute-exacerbation of interstitial lung disease
    Van Hollebeke, Marine
    Chohan, Karan
    Adams, Colin J.
    Fisher, Jolene H.
    Shapera, Shane
    Fidler, Lee
    Goligher, Ewan C.
    Martinu, Tereza
    Wickerson, Lisa
    Mathur, Sunita
    Singer, Lianne G.
    Reid, W. Darlene
    Rozenberg, Dmitry
    CHRONIC RESPIRATORY DISEASE, 2024, 21